atezolizumab plus bevacizumab (n=334) vs. Standard of Care (SoC) (n=334)
randomized controlled trial
atezolizumab plus bevacizumab
1200 mg intravenous atezolizumab plus intravenous bevacizumab 15 mg/kg every 3 weeks for up to 12 months or 17 cycles
active surveillance
Patients randomly allocated to active surveillance were permitted to receive crossover treatment with atezolizumab plus bevacizumabat investigator discretion on independent review facility confirmation of disease recurrence. Resection or ablation of recurrent lesions was allowed before crossover treatment.
mHCC - (neo)adjuvant (NA)
open label
34 centres in 26 countries
IMbrave-150, 2020 NCT03434379
atezolizumab plus bevacizumab (n=336) vs. sorafenib (n=165)
randomized controlled trial
atezolizumab-bevacizumab
atezolizumab–bevacizumab group received 1200 mg of atezolizumab plus 15 mg per kilogram of body weight of bevacizumab intravenously every 3 weeks
sorafenib
400 mg of sorafenib orally twice daily
Dose modifications were not permitted in the atezolizumab–bevacizumab group but were allowed in the sorafenib group.
mHCC - 1st line (L1)
open design
111 sites in 17 countries
P3/two sided One analysis of PFS, two interim analyses, and a final analysis of OS. Repartition, reallocation and hierarchy OS PFS and ORR (arm A then arm B)
In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progressionÂfree survival outcomes than sorafenib